tetano
Editor, Senior Moderator
Vaccine
. 2023 Jun 13;S0264-410X(23)00687-4.
doi: 10.1016/j.vaccine.2023.06.023. Online ahead of print. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022
Emily Jane Woo[SUP] 1 [/SUP], Julianne Gee[SUP] 2 [/SUP], Paige Marquez[SUP] 2 [/SUP], James Baggs[SUP] 3 [/SUP], Winston E Abara[SUP] 2 [/SUP], Michael M McNeil[SUP] 2 [/SUP], Rositsa B Dimova[SUP] 4 [/SUP], John R Su[SUP] 2 [/SUP]
Affiliations
Background: On 2/27/2021, FDA authorized Janssen COVID-19 Vaccine (Ad.26.COV2.S) for use in individuals 18 years of age and older. Vaccine safety was monitored using the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance system, and v-safe, a smartphone-based surveillance system.
Methods: VAERS and v-safe data from 2/27/2021 to 2/28/2022 were analyzed. Descriptive analyses included sex, age, race/ethnicity, seriousness, AEs of special interest (AESIs), and cause of death. For prespecified AESIs, reporting rates were calculated using the total number of doses of Ad26.COV2.S administered. For myopericarditis, observed-to-expected (O/E) analysis was performed based on the number verified cases, vaccine administration data, and published background rates. Proportions of v-safe participants reporting local and systemic reactions, as well as health impacts, were calculated.
Results: During the analytic period, 17,018,042 doses of Ad26.COV2.S were administered in the United States, and VAERS received 67,995 reports of AEs after Ad26.COV2.S vaccination. Most AEs (59,750; 87.9 %) were non-serious and were similar to those observed during clinical trials. Serious AEs included COVID-19 disease, coagulopathy (including thrombosis with thrombocytopenia syndrome; TTS), myocardial infarction, Bell's Palsy, and Guillain-Barré syndrome (GBS). Among AESIs, reporting rates per million doses of Ad26.COV2.S administered ranged from 0.06 for multisystem inflammatory syndrome in children to 263.43 for COVID-19 disease. O/E analysis revealed elevated reporting rate ratios (RRs) for myopericarditis; among adults ages 18-64 years, the RR was 3.19 (95 % CI 2.00, 4.83) within 7 days and 1.79 (95 % CI 1.26, 2.46) within 21 days of vaccination. Of 416,384 Ad26.COV2.S recipients enrolled into v-safe, 60.9 % reported local symptoms (e.g. injection site pain) and 75.9 % reported systemic symptoms (e.g., fatigue, headache). One-third of participants (141,334; 33.9 %) reported a health impact, but only 1.4 % sought medical care.
Conclusion: Our review confirmed previously established safety risks for TTS and GBS and identified a potential safety concern for myocarditis.
Keywords: Ad.26.COV2.S COVID-19 vaccine; Adverse event; Coronavirus; SARS-CoV-2; V-safe; VAERS.
. 2023 Jun 13;S0264-410X(23)00687-4.
doi: 10.1016/j.vaccine.2023.06.023. Online ahead of print. Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021-February 2022
Emily Jane Woo[SUP] 1 [/SUP], Julianne Gee[SUP] 2 [/SUP], Paige Marquez[SUP] 2 [/SUP], James Baggs[SUP] 3 [/SUP], Winston E Abara[SUP] 2 [/SUP], Michael M McNeil[SUP] 2 [/SUP], Rositsa B Dimova[SUP] 4 [/SUP], John R Su[SUP] 2 [/SUP]
Affiliations
- PMID: 37321898
- DOI: 10.1016/j.vaccine.2023.06.023
Background: On 2/27/2021, FDA authorized Janssen COVID-19 Vaccine (Ad.26.COV2.S) for use in individuals 18 years of age and older. Vaccine safety was monitored using the Vaccine Adverse Event Reporting System (VAERS), a national passive surveillance system, and v-safe, a smartphone-based surveillance system.
Methods: VAERS and v-safe data from 2/27/2021 to 2/28/2022 were analyzed. Descriptive analyses included sex, age, race/ethnicity, seriousness, AEs of special interest (AESIs), and cause of death. For prespecified AESIs, reporting rates were calculated using the total number of doses of Ad26.COV2.S administered. For myopericarditis, observed-to-expected (O/E) analysis was performed based on the number verified cases, vaccine administration data, and published background rates. Proportions of v-safe participants reporting local and systemic reactions, as well as health impacts, were calculated.
Results: During the analytic period, 17,018,042 doses of Ad26.COV2.S were administered in the United States, and VAERS received 67,995 reports of AEs after Ad26.COV2.S vaccination. Most AEs (59,750; 87.9 %) were non-serious and were similar to those observed during clinical trials. Serious AEs included COVID-19 disease, coagulopathy (including thrombosis with thrombocytopenia syndrome; TTS), myocardial infarction, Bell's Palsy, and Guillain-Barré syndrome (GBS). Among AESIs, reporting rates per million doses of Ad26.COV2.S administered ranged from 0.06 for multisystem inflammatory syndrome in children to 263.43 for COVID-19 disease. O/E analysis revealed elevated reporting rate ratios (RRs) for myopericarditis; among adults ages 18-64 years, the RR was 3.19 (95 % CI 2.00, 4.83) within 7 days and 1.79 (95 % CI 1.26, 2.46) within 21 days of vaccination. Of 416,384 Ad26.COV2.S recipients enrolled into v-safe, 60.9 % reported local symptoms (e.g. injection site pain) and 75.9 % reported systemic symptoms (e.g., fatigue, headache). One-third of participants (141,334; 33.9 %) reported a health impact, but only 1.4 % sought medical care.
Conclusion: Our review confirmed previously established safety risks for TTS and GBS and identified a potential safety concern for myocarditis.
Keywords: Ad.26.COV2.S COVID-19 vaccine; Adverse event; Coronavirus; SARS-CoV-2; V-safe; VAERS.